证券代码：002286 证券简称：保龄宝 公告编号：2026-004 保龄宝生物股份有限公司 关于实际控制人控制的企业股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚 假记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 保龄宝生物股份有限公司（以下简称"公司"或"保龄宝"）近日 接到深圳松径投资合伙企业（有限合伙）（以下简称"松径投资"）通 知，获悉其所持有本公司的股份被质押。松径投资为公司实际控制人之 一戴斯聪先生控制的企业。具体事项如下： （一）股东股份质押基本情况 | 股 | | 是否为控 | | 占其 | 占公 | | 是否 | | | | 质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 东 | | 股股东或 | | 所持 | 司总 | | 为补 | | | | 押 | | | | 第一大股 | 本次质 | | | 是否为 | | 质押起 | 质押到 | 质权人 | | | 名 | | | 押数量 | 股份 | 股本 | 限售股 | 充质 | 始日 | ...

Market Overview - The agricultural processing sector increased by 0.85% on January 23, with Huazi Industrial leading the gains [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] Stock Performance - Huazi Industrial (600191) closed at 13.77, up 5.60% with a trading volume of 220,000 shares and a turnover of 304 million yuan [1] - Guanyi Co. (600251) closed at 10.64, up 4.62% with a trading volume of 196,600 shares and a turnover of 205 million yuan [1] - Other notable performers include: - Guotou Zhonglu (600962) at 24.19, up 2.07% [1] - Zhongliang Sugar Industry (600737) at 17.62, up 1.56% [1] - Jingliang Holdings (000505) at 7.49, up 1.35% [1] Fund Flow Analysis - The agricultural processing sector experienced a net outflow of 90.7981 million yuan from institutional investors and 81.4544 million yuan from speculative funds, while retail investors saw a net inflow of 172 million yuan [2] - Key stocks with significant fund flows include: - Guanyi Co. (600251) with a net outflow of 22.9738 million yuan from institutional investors [3] - Huazi Industrial (600191) with a net inflow of 13.5975 million yuan from institutional investors [3] - Baolingbao (002286) with a net inflow of 9.7206 million yuan from institutional investors [3]

Core Insights - On January 21, 2026, a block trade of 5.7 million shares of Baolingbao was executed, amounting to 54.891 million yuan, which represented 27.06% of the total trading volume for that day [1][2] - The transaction price was 9.63 yuan per share, reflecting a discount of 2.83% compared to the market closing price of 9.91 yuan [1] Summary by Categories Trading Details - The block trade involved 5.7 million shares at a price of 9.63 yuan per share [2] - The total transaction value was 54.891 million yuan [2] - The trade was conducted by an institutional buyer through Guosheng Securities [2] Market Impact - The transaction accounted for 27.06% of the total trading volume on that day, indicating significant market activity [1][2] - The discount of 2.83% from the closing price may suggest a strategic move by the seller to liquidate shares quickly [1]

Core Viewpoint - The major shareholder of Baolingbao Bio-Pharmaceutical Co., Ltd., Ningbo Baopu Futong Asset Management Center (Limited Partnership), has completed its share reduction plan, selling a total of 11,416,905 shares, which represents approximately 3% of the company's total share capital [2][3]. Group 1: Share Reduction Plan - The shareholder, Baopu Futong, initially held 27,046,297 shares, accounting for 7.10684% of the total share capital, and planned to reduce its holdings by up to 11,417,020 shares within a specified period [2]. - The reduction was executed through both centralized bidding and block trading, with a maximum of 2% (7,611,347 shares) allowed to be sold via block trading and 1% (3,805,673 shares) via centralized bidding within any consecutive 90-day period [2][3]. Group 2: Share Reduction Details - The shares were acquired through a private transfer in December 2016, with the selling price ranging from 11.31 to 11.45 CNY per share for centralized bidding and from 8.64 to 8.66 CNY per share for block trading [3]. - The implementation of the reduction plan was in compliance with relevant laws and regulations, ensuring that it did not affect the company's control structure or governance [4][5].

Core Viewpoint - The major shareholder, Baopifutong, has reduced its stake in the company from 7.10684% to 4.10687% through a planned share reduction, which will not affect the company's control or ongoing operations [1] Group 1 - Baopifutong initially held 27,046,300 shares, representing 7.10684% of the total share capital [1] - The shareholder disclosed a reduction plan on October 21, 2025, intending to reduce up to 11,417,000 shares, which is no more than 3% of the total share capital, between November 11, 2025, and February 10, 2026 [1] - As of January 19, 2026, Baopifutong completed the reduction by selling 11,416,900 shares through centralized bidding and block trading [1] Group 2 - After the reduction, Baopifutong's remaining shares amount to 15,629,400, which is 4.10687% of the total share capital [1] - The reduction of shares will not lead to a change in the company's control [1] - The company's ongoing operations remain unaffected by this share reduction [1]

证券代码：002286 证券简称：保龄宝 公告编号：2026-002 保龄宝生物股份有限公司 关于持股5%以上的股东减持计划实施完成的公告 股东宁波趵朴富通资产管理中心(有限合伙)保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 保龄宝生物股份有限公司(以下简称"保龄宝""公司")于2025年10月21日 披露了《关于持股5%以上股东减持股份预披露的公告》 (公告编号:2025-056)，持 有公司股份27,046,297股（占本公司总股本比例7.10684%）的大股东宁波趵朴富 通资产管理中心(有限合伙)（以下简称"趵朴富通"）计划在减持预披露公告披 露之日起十五个交易日后的三个月内(2025年11月11日至2026年2月10日)以集中竞 价交易方式和大宗交易方式合计减持保龄宝股份不超过11,417,020股，即不超过公 司总股本的3%。其中，在任意连续90日内通过大宗交易方式减持公司股份的总 数，合计不超过公司总股本的2%（7,611,347股）；任意连续90日内通过集中竞价 交易方式减持公司股份的总数， ...

Core Viewpoint - The article discusses the rising interest and potential of D-allohexose (D-阿洛酮糖) as a sugar substitute in the food and beverage industry, highlighting its approval as a new food ingredient and the contrasting dynamics between production and consumer market adoption [1][5][21]. Production Dynamics - Major food and beverage companies are actively seeking to test D-allohexose, which is seen as a promising sugar alternative due to its low caloric content and ability to participate in the Maillard reaction [1][3]. - Following its approval on July 2, 2025, there was a significant surge in market interest, with a 4985% increase in the WeChat index for D-allohexose and notable stock price increases for related companies [1][3]. - Production capacity is rapidly expanding, with companies like Baolingbao and Jinhe Industrial planning to increase their annual production capacities to tens of thousands of tons [9][10][11]. Market Adoption - Despite the production enthusiasm, the consumer market remains relatively quiet, with only a few products incorporating D-allohexose, such as Naixue's tea and a probiotic drink from Youyi C [4][12]. - The slow market adoption is attributed to the lengthy process of product development and the high cost of D-allohexose compared to traditional sugars, which limits its immediate application in consumer products [14][15][21]. Cost and Production Challenges - The cost of D-allohexose remains a significant barrier, with prices ranging from 20,000 to 24,000 yuan per ton, compared to 6,000 yuan for white sugar [15][17]. - The production methods for D-allohexose, including fermentation and enzymatic conversion, present technical challenges that contribute to its higher costs [18][19]. Regulatory and Market Position - D-allohexose is classified as a new food ingredient rather than a food additive, allowing for broader applications across various food categories, unlike other sweeteners that are limited to specific uses [23][26]. - The article suggests that D-allohexose may find its initial applications in high-end markets where consumers are less price-sensitive and more focused on health benefits [21][22].

Core Viewpoint - The company, Baolingbao (002286.SZ), has a diverse client base including well-known domestic and international brands, and is expanding its product offerings in the health and nutrition sector, particularly with the approval of its lactulose raw material drug for future domestic sales [1] Group 1: Client Base - The company’s main clients include prominent brands such as Yili, Coca-Cola, Yuanqi Forest, Abbott, Feihe Dairy, Junlebao, Holley, Dongpeng Beverage, and Mixue [1] Group 2: Product Development - The core products of the company include prebiotics, dietary fibers, and sugar-reducing sweeteners, with detailed business and industry development information available in the company's 2025 semi-annual report [1] Group 3: Regulatory Approvals - In October 2025, the company obtained a production license for lactulose raw material from the Shandong Provincial Drug Administration, pending further registration with the National Medical Products Administration for domestic sales [1] - Currently, the lactulose raw material is only exported to select overseas markets, but future approvals in major countries are expected to enhance sales revenue and operational performance [1]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2026-01-19 | 002286 | 保龄宝 | 8.64 | 339.89 | 2,936.63 机构专用 | | 国盛证券有限责任 | | | | | | | | | 公司宁波桑田路证 | | | | | | | | | 券营业部 | 1月19日，保龄宝大宗交易成交339.89万股，成交额2936.63万元，占当日总成交额的15.99%，成交价8.64元，较市场收盘价 9.82元折价12.02%。 ...

（编辑 楚丽君） 证券日报网讯 1月16日，保龄宝在互动平台回答投资者提问时表示，阿洛酮糖价格受市场供需影响。公 司在阿洛酮糖的生产技术和成本控制方面具备一定优势，公司将通过工艺优化、原材料和能源成本控制 以及规模化生产等措施保持竞争力。 ...